Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, of the upcoming lead plaintiff deadline on November 7, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Savara securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 7, 2025 [2] - The lawsuit claims that Savara's defendants made false or misleading statements regarding the approval process of the MOLBREEVI Biologics License Application (BLA) [4] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success and recognition in this field [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Investors have the option to select their counsel or remain absent from the class until it is certified [6]
SVRA IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action – SVRA